Edition:
India

Hansa Medical AB (HMED.ST)

HMED.ST on Stockholm Stock Exchange

279.20SEK
23 Jan 2018
Change (% chg)

-0.60kr (-0.21%)
Prev Close
279.80kr
Open
281.20kr
Day's High
282.80kr
Day's Low
277.40kr
Volume
85,718
Avg. Vol
173,152
52-wk High
290.00kr
52-wk Low
96.75kr

Chart for

About

Hansa Medical AB is a Sweden-based biopharmaceutical company with focus on immunomodulatory enzymes for treatment and prevention of rare and severe autoimmune conditions and transplant rejection. The Company’s operations consist of research and development for drug discovery. The Company conducts several projects, among which... (more)

Overall

Beta: 1.83
Market Cap(Mil.): kr7,554.32
Shares Outstanding(Mil.): 35.05
Dividend: --
Yield (%): --

Financials

BRIEF-‍Hansa Medical's board has resolved on a directed share issue of SEK 545 mln​

* ‍HANSA MEDICAL'S BOARD OF DIRECTORS HAS RESOLVED ON A DIRECTED SHARE ISSUE OF SEK 545 MILLION​ Source text for Eikon: Further company coverage:

30 Nov 2017

BRIEF-‍Hansa Medical Contemplates Directed Share Issue To Raise About Sek 545 mln​

* ‍HANSA MEDICAL CONTEMPLATES A DIRECTED SHARE ISSUE TO RAISE APPROXIMATELY SEK 545 MILLION​

29 Nov 2017

BRIEF-Hansa Medical Q3 operating loss up at SEK ‍​37.4 mln

* Q3 OPERATING LOSS SEK ‍​37.4 MILLION VERSUS LOSS SEK 27.0 MILLION YEAR AGO

14 Nov 2017

BRIEF-Hansa Medical: sudden death of CEO Göran Arvidson​

* ‍BIRGIT STATTIN NORINDER WILL TAKE OVER ROLE AS CHAIRMAN OF BOARD UNTIL FURTHER NOTICE​ Source text for Eikon: Further company coverage: (Gdynia Newsroom)

08 Nov 2017

Hansa Medical shares gain on good kidney transplant drug news

LONDON Shares in Sweden's Hansa Medical jumped 12 percent on Thursday after research showed its experimental drug allowed doctors to perform successful kidney transplants in 24 out of 25 patients with a particularly high risk of organ rejection.

03 Aug 2017

Earnings vs. Estimates